Lixisenatide clinical trials: 47 trials
Page 1 of 1
Read 47 Lixisenatide clinical trials with posted results or linked papers with results in PepBank.
- Evaluation of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Acute Coronary Syndrome During Treatment With AVE0010 (Lixisenatide)
NCT01147250 · Phase 3 · Completed
Posted results
- Efficacy and Safety of Insulin Glargine/ Lixisenatide Fixed Ratio Combination Compared to Insulin Glargine Alone and Lixisenatide Alone on Top of Metformin in Patients With T2DM
NCT02058147 · Phase 3 · Completed
Posted results
- Efficacy and Safety of Lixisenatide Versus Insulin Glulisine on Top of Insulin Glargine With or Without Metformin in Type 2 Diabetic Patients
NCT01768559 · Phase 3 · Completed
Posted results
- GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Sulfonylurea
NCT00713830 · Phase 3 · Completed
Posted results
- Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 Diabetes
NCT02058160 · Phase 3 · Completed
Posted results
- GLP-1 Receptor Agonist Lixisenatide (Morning or Evening) in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin
NCT00712673 · Phase 3 · Completed
Posted results
- GLP-1 Receptor Agonist Lixisenatide Versus Exenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin
NCT00707031 · Phase 3 · Completed
Posted results
- iGlarLixi vs IDegAsp in Chinese Participants After OAD(s)
NCT05413369 · Phase 3 · Completed
Posted results
- Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period
NCT02787551 · Phase 3 · Completed
Posted results
- GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Basal Insulin
NCT00715624 · Phase 3 · Completed
Posted results
- GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin
NCT00763451 · Phase 3 · Completed
Posted results
- GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Pioglitazone
NCT00763815 · Phase 3 · Completed
Posted results
- Comparison of Lixisenatide Injected Prior to the Main Meal of the Day Versus Prior to Breakfast in Type 2 Diabetic Patients on Metformin
NCT01517412 · Phase 3 · Completed
Posted results
- 24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin Glargine
NCT00975286 · Phase 3 · Completed
Posted results
- Efficacy and Safety of Liraglutide Versus Lixisenatide as add-on to Metformin in Subjects With Type 2 Diabetes
NCT01973231 · Phase 4 · Completed
Posted results
- Efficacy and Safety of Lixisenatide in Patients With Type 2 Diabetes Mellitus Insufficiently Controlled by Metformin
NCT01169779 · Phase 3 · Completed
Posted results
- GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation in Monotherapy
NCT00688701 · Phase 3 · Completed
Posted results
- Efficacy and Safety of Lixisenatide Versus Placebo on Top of Basal Insulin and/or Oral Antidiabetic Treatment in Older Type 2 Diabetic Patients
NCT01798706 · Phase 3 · Completed
Posted results
- 24-week Study Comparing Lixisenatide to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 Years
NCT00976937 · Phase 3 · Completed
Posted results
- GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Basal Insulin +/- Sulfonylurea (GETGOAL-L-ASIA)
NCT00866658 · Phase 3 · Completed
Posted results
- Efficacy and Safety of Soliqua Versus Lantus in Ethnically/Racially Diverse Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic Agents
NCT03434119 · Phase 3 · Terminated
Posted results
- Effect of Soliqua 100/33 on Time in Range From Continuous Glucose Monitoring in Insulin-naive Patients With Very Uncontrolled Type 2 Diabetes Mellitus
NCT05114590 · Phase 4 · Completed
Posted results
- GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation in Monotherapy (GETGOAL-MONO Japan LTS)
NCT00905255 · Phase 3 · Completed
Posted results
- Feasibility of Once/Daily Administered GLP/1 Receptoragonist (Lixisenatide) in Combination With Basal Insulin
NCT02168491 · Phase 3 · Completed
Posted results
- Evaluation of Insulin Glargine/Lixisenatide Fixed Ratio Combination in Patients With Type 2 Diabetes Insufficiently Controlled With Oral Antidiabetic Drug(s)
NCT03798054 · Phase 3 · Completed
Linked paper with results
- Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (LixiLan) to Insulin Glargine Alone on Top of Oral Anti-diabetic Drugs (OADs) With Type 2 Diabetes in Japan
NCT02752828 · Phase 3 · Completed
Linked paper with results
- Efficacy and Safety of LixiLan Versus Insulin Glargine Alone Both With Metformin in Japanese With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic Drugs
NCT02752412 · Phase 3 · Completed
Linked paper with results
- Assessment of the Efficacy and Safety of Lixisenatide in Patients With Type 2 Diabetes Insufficiently Controlled With Basal Insulin +/- Metformin
NCT01632163 · Phase 3 · Completed
Linked paper with results
- Comparison of the Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Ratio Combination to Insulin Glargine in Patients With Type 2 Diabetes Insufficiently Controlled on Basal Insulin
NCT03798080 · Phase 3 · Completed
Linked paper with results
- Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (LixiLan) to Lixisenatide on Top of Oral Anti-diabetic Drugs (OADs) With Type 2 Diabetes in Japan
NCT02749890 · Phase 3 · Completed
Linked paper with results
- Safety Assessment of Lyxumia (Lixisenatide) and Sulfonylurea as Add-on Treatment to Basal Insulin in Uncontrolled Patients With Type 2 Diabetes Mellitus Who Elect to Fast During Ramadan
NCT02941367 · Phase 4 · Completed
Linked paper with results
- Effect of Lixisenatide on Postprandial Plasma Glucose Compared to Sitagliptin in Combination With Insulin Glargine
NCT02200991 · Phase 4 · Completed
Linked paper with results
- The Effect of Soliqua on Glucose Variability in Type 2 Patients Among South Asians
NCT03819790 · Phase 4 · Completed
Linked paper with results
- Effect of LIXIsenatide on the Renal System
NCT02276196 · Phase 4 · Completed
Linked paper with results
- Study on Lixisenatide and Counterregulation to Hypoglycemia
NCT02020629 · Phase 4 · Completed
Linked paper with results
- Lixisenatide-The Effects on Glucose and Lipid Metabolism in Type 2 Diabetes
NCT02049034 · Phase 4 · Completed
Linked paper with results
- Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Combination Versus Insulin Glargine Alone on Top of Metformin in Type 2 Diabetic Patients
NCT01476475 · Phase 2 · Completed
Posted results
- Effects of Lixisenatide Compared to Liraglutide on the Postprandial Plasma Glucose in Patients With Type 2 Diabetes
NCT01175473 · Phase 2 · Completed
Posted results
- Pharmacodynamic Effects of Lixisenatide Compared to Liraglutide in Patients With Type 2 Diabetes Not Adequately Controlled With Insulin Glargine With or Without Metformin
NCT01596504 · Phase 2 · Completed
Posted results
- Dose Ranging Study of the GLP-1 Agonist AVE0010 in Metformin-Treated Subjects With Type 2 Diabetes Mellitus
NCT00299871 · Phase 2 · Completed
Linked paper with results
- Study to Evaluate the Effect of Lixisenatide in Patient With Parkinson's Disease
NCT03439943 · Phase 2 · Completed
Linked paper with results
- Drug Trial of Lixisenatide on Gastric Emptying and Blood Pressure Drops in Type 2 Diabetics and Healthy People
NCT02308254 · Phase 1/2 · Status unknown
Linked paper with results
- Effects of Victoza® Versus Lyxumia® on Gastroesophageal Reflux, Gastric Emptying and Gastric Acid Secretion
NCT02231658 · Phase 1 · Terminated
Linked paper with results
- A Study on Safety, Pharmacokinetics and Pharmacodynamics of Lixisenatide in Pediatric Patients With Type 2 Diabetes Mellitus (T2DM)
NCT02803918 · Phase 1 · Completed
Linked paper with results
- Postprandial Glucodynamic Response to Insulin Glargine/Lixisenatide Fixed Ratio Combination in Japanese Patients With Type 2 Diabetes Mellitus
NCT02713477 · Phase 1 · Completed
Linked paper with results
- The Impact of Lixisenatide on Postprandial Glucose Tolerance in Pancreatectomised Subjects
NCT02640118 · Not applicable · Completed
Linked paper with results
- Pathophysiological Study of the Increase in Pancreatic Volume in Type 2 Diabetes Treatments.
NCT02244164 · Not applicable · Terminated
Linked paper with results